Regeneron Pharmaceuticals Stock Price and Value Analysis

Regeneron Pharmaceuticals (NasdaqGS:REGN) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Regeneron Pharmaceuticals to reach your target.

Target type

REGN Free Cash Flow Trend

Free Cash Flow trendline for REGN
Free Cash Flow trendline for Regeneron Pharmaceuticals
CSV

Based on historical returns, we believe that Regeneron Pharmaceuticals can grow its free cash at a rate of about 7%. That's positive!

AdvantagesDisadvantages
  • This company is making money at a decent rate.
  • This company has a low dividend yield.
  • This company has wild ups and downs.
  • This company is less known than others.
  • This stock looks overpriced.

Inside the REGN Numbers

REGN Price
(Regeneron Pharmaceuticals stock price per share)
$920.69
[?] REGN Fair Price
(based on intrinsic value)
$394.54
[?] REGN Safety Price (based on a variable margin of safety) $236.72
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 3% higher than other Healthcare stocks
[?] PE Ratio versus Industry 71% lower than other Drug Manufacturers - General stocks
[?] Cash Yield 0.49%
[?] Free Cash Flow Jitter 53%
[?] Dividend Yield 0.40% (tax impact)
Shares Shorted 2,217,114

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 2,217,114 shares shorted. With 96,364,049 shares available for purchase and an average trading volume over the past 10 trading days of 916,830, it would take at least 2.4 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2008 872589 -124
2009 872589 -136
2010 872589 21.9
2011 872589 -214
2012 872589 -142
2013 872589 497
2014 872589 613
2015 872589 1,076
2016 872589 1,140
2017 872589 917
2018 872589 1,759
2019 872589 1,975
2020 872589 2,176
2021 872589 6,631
2022 872589 4,501
2023 872589 4,013
2024 872589 3,774
2025 872589 4,276

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 14 fiscal years from 2008 to 2025 with positive net income, operating cash flow totaled $38,723 million against net income of $37,590 million, or 1.03 times. Net income was negative in 4 of the 18 years, and those years are left out of the ratio.

In 2025, capital expenditures were $898 million, 18.0% of operating cash flow of $4,979 million, which leaves an estimated $4,081 million after capex. Across the 14 years with reported capex, it averaged 18.0% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2008 -79.1 -89.1 34.9 n/a
2009 -67.8 -69.9 97.3 n/a
2010 -104 99.2 99.7 n/a
2011 -222 -142 57.2 n/a
2012 750 -74.6 49.3 -0.10
2013 414 589 156 1.42
2014 338 752 333 2.23
2015 636 1,331 678 2.09
2016 896 1,486 512 1.66
2017 1,199 1,307 273 1.09
2018 2,444 2,195 383 0.90
2019 2,116 2,430 430 1.15
2020 3,513 2,618 615 0.75
2021 8,075 7,081 552 0.88
2022 4,338 5,015 590 1.16
2023 3,954 4,594 719 1.16
2024 4,413 4,421 756 1.00
2025 4,505 4,979 898 1.11

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 8 fiscal years from 2018 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $29,105 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In the 1 of those years with dividend payment facts, dividends paid totaled $370 million, 8.7% of the estimated free cash flow of those years. Estimated free cash flow was at least the dividends paid in 1 of those 1 years.

In 7 of the 8 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $18,128 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2025, dividends and cash spent repurchasing shares together were $3,809 million, 89.1% of estimated free cash flow of $4,276 million.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2018 1,759 n/a 4.4 4.4 0.3%
2019 1,975 n/a 276 276 14.0%
2020 2,176 n/a 5,847 5,847 268.7%
2021 6,631 n/a 1,645 1,645 24.8%
2022 4,501 n/a 2,083 2,083 46.3%
2023 4,013 n/a 2,235 2,235 55.7%
2024 3,774 n/a 2,603 2,603 69.0%
2025 4,276 370 3,439 3,809 89.1%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $238 million in 2008 and $14,343 million in 2025, a compound annual growth rate of 27.3% over 17 years. The starting revenue was under 10% of the latest, so that rate comes from a small base and says little about recent growth.

Revenue rose 1.0% from 2024 to 2025.

Our estimated free cash flow was $4,276 million in 2025, 29.8% of revenue. In 2008 the estimated margin was negative 52.0%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2008 238 -124 -52.0%
2009 379 -136 -35.9%
2010 459 21.9 4.8%
2011 446 -214 -48.0%
2012 1,378 -142 -10.3%
2013 2,105 497 23.6%
2014 2,820 613 21.8%
2015 4,104 1,076 26.2%
2016 4,860 1,140 23.5%
2017 5,872 917 15.6%
2018 5,146 1,759 34.2%
2019 6,558 1,975 30.1%
2020 8,497 2,176 25.6%
2021 16,072 6,631 41.3%
2022 12,173 4,501 37.0%
2023 13,117 4,013 30.6%
2024 14,202 3,774 26.6%
2025 14,343 4,276 29.8%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $3,118 million against total liabilities of $9,302 million, or 33.5% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 22.9% of total assets in 2025, compared with 46.5% in 2009, a decrease of 23.5 percentage points.

Stockholders equity was $31,257 million in 2025, compared with $397 million in 2009, a rise of 7778.0%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 12.9% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2009 741 207 344 397
2010 1,089 113 562 528
2011 1,324 484 838 486
2012 2,080 230 824 1,257
2013 2,951 536 986 1,965
2014 3,838 649 1,287 2,550
2015 5,609 809 1,954 3,655
2016 6,973 535 2,524 4,449
2017 8,764 813 2,620 6,144
2018 11,735 1,468 2,977 8,757
2019 14,805 1,618 3,716 11,090
2020 17,163 2,194 6,138 11,025
2021 25,435 2,886 6,666 18,769
2022 29,215 3,106 6,551 22,664
2023 33,080 2,730 7,107 25,973
2024 37,759 2,488 8,406 29,354
2025 40,559 3,118 9,302 31,257

What the Price Implies

How to read this: discounted cash flow, intrinsic value.

At today's price of $920.69, our model's value equals that price if free cash flow grows an average of 34.3 percent a year over the 10 projection years. Our model assumes 7.2 percent a year for this stock, so the price implies growth of 34.3 percent, which is above the 7.2 percent our model assumes. This is the growth the price implies under our model, not a forecast of growth or a price target.

At 34.3 percent a year, free cash flow would grow about 19.1 times over the 10 years.

The table shows the same calculation at a price 20 percent lower and 20 percent higher than today's price, and the model's own growth rate at its fair price.

The model starts from the company's average free cash flow of $463 million, grows it over 10 years along the year-by-year growth path stored for this stock (the pace fades over the years, and the implied rate keeps that shape, so the rates here are 10-year averages), discounts it at 10.1 percent a year, adds a terminal value that grows 2.5 percent a year after year 10, adds the company's net worth, and divides by shares outstanding.

The baseline is the company's average free cash flow, and cyclical companies can mislead it.

CasePrice per shareAverage annual free cash flow growth
20 percent below the current price $736.55 29.1%
Current price $920.69 34.3%
20 percent above the current price $1,104.83 38.2%
Our model (stored fair price) $394.54 7.2%

Model assumptions: 10.1 percent discount rate, 2.5 percent terminal growth, 10 projection years. To try your own growth rate, use the intrinsic value calculator on this page. It uses a simpler single-rate model, so its results will not match the figures above exactly.

Price Versus Our Estimated Value

Free cash flow was positive in 14 out of 18 reported years for Regeneron Pharmaceuticals, using only its current SEC filer.

Free cash flow is volatile from year to year, with a variability measure of 53%.

At $920.69, the price is above our fair value estimate of $394.54 for Regeneron Pharmaceuticals.

Its dividend yield is 0.40%.

Before you act on any of this, read what a margin of safety means and check the company's own filings.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 3% above the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 71% below the average for stocks in the Drug Manufacturers - General industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Drug Manufacturers - General industry, the ones closest in market capitalization to Regeneron Pharmaceuticals, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Regeneron Pharmaceuticals (REGN) 95,243 20.4 0.4% 0.5% 133% above
Bristol-Myers Squibb Company (BMY) 120,192 13.0 4.3% 1.2% 85% above
Teva Pharmaceutical Industries Limited (TEVA) 44,970 89.6 - 13.5% 47% below
Pfizer (PFE) 156,176 39.1 7.8% 11.6% 63% below
Zoetis (ZTS) 32,144 13.5 2.6% - 865% above
United Therapeutics Corporation (UTHR) 23,625 20.9 - 1.5% 30% above
Viatris (VTRS) 22,505 - 2.4% - 2% below

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 872589.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow was negative in 4 of the 18 years we have.
  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: REGN annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in REGN

Does Regeneron Pharmaceuticals have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: REGN

This example shows how we apply the Trendshare checklist to REGN: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 920.69
    • Market cap: $95B
    • EPS: 45.24
  2. Step 2 — Valuation checks

    • P/E: 20.351
    • FCF yield: 0.5%
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.